Substituting Lantus (insulin glargine [rDNA origin] inj) for a thiazolidinedione vs. a 3rd oral agent as add-on therapy in patients failing a thiazolidinedione and sulfonylurea or metformin combination.

Trial Profile

Substituting Lantus (insulin glargine [rDNA origin] inj) for a thiazolidinedione vs. a 3rd oral agent as add-on therapy in patients failing a thiazolidinedione and sulfonylurea or metformin combination.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2009

At a glance

  • Drugs Antihyperglycaemics; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Mar 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 15 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top